TY - JOUR
TI - Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
AU - Delforge, M.
AU - Bladé, J.
AU - Dimopoulos, M.A.
AU - Facon, T.
AU - Kropff, M.
AU - Ludwig, H.
AU - Palumbo, A.
AU - Van Damme, P.
AU - San-Miguel, J.F.
AU - Sonneveld, P.
JO - The lancet oncology
PY - 2010
VL - 11
TODO - 11
SP - 1086-1095
PB - 
SN - null
TODO - 10.1016/S1470-2045(10)70068-1
TODO - alpha tocopherol;  bortezomib;  carfilzomib;  cisplatin;  dexamethasone;  doxorubicin;  glutamine;  glutathione;  immunoglobulin enhancer binding protein;  lenalidomide;  levacecarnine;  melphalan;  myelin associated glycoprotein;  pomalidomide;  prednisone;  thalidomide;  thioctic acid;  tumor necrosis factor alpha;  vincristine;  vitamin B group, ataxia;  autologous stem cell transplantation;  autonomic dysfunction;  bradycardia;  cell survival;  clinical trial;  comorbidity;  constipation;  cytokine production;  demyelination;  denervation;  diarrhea;  disease predisposition;  down regulation;  drug dose comparison;  drug dose reduction;  drug megadose;  drug response;  drug withdrawal;  gait disorder;  gastrointestinal symptom;  hematologic disease;  human;  hypesthesia;  hypothyroidism;  immunomodulation;  impotence;  incidence;  low drug dose;  motor dysfunction;  motor neuropathy;  multiple myeloma;  muscle cramp;  nerve conduction;  nerve fiber;  neuropathic pain;  neuropathy;  neuroprotection;  neurotoxicity;  nonhuman;  orthostatic hypotension;  paresthesia;  pathophysiology;  perikaryon;  peripheral nerve;  peripheral neuropathy;  phocomelia;  pleiotropy;  priority journal;  review;  Schwann cell;  sensory dysfunction;  sensory neuropathy;  sexual dysfunction;  skin biopsy;  skin tingling;  spinal ganglion;  teratogenicity;  treatment duration;  tremor;  vitamin supplementation;  weakness, Antineoplastic Agents;  Boronic Acids;  Humans;  Incidence;  Multiple Myeloma;  Peripheral Nervous System Diseases;  Pyrazines;  Risk Assessment;  Risk Factors;  Thalidomide;  Treatment Outcome
TODO - Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma. As a result, these drugs have become cornerstones of current antimyeloma treatment regimens. However, after several years of clinical experience it has become apparent that peripheral neuropathy is the most common and potentially disabling non-haematological side-effect associated with thalidomide and bortezomib. Maximising treatment benefit while preserving quality of life therefore requires a careful balance between achieving optimum activity and minimising toxicity, including neuropathy, to further enhance efficacy. In this review, we discuss all aspects of drug-induced peripheral neuropathy in myeloma, with a particular focus on thalidomide and bortezomib. © 2010 Elsevier Ltd.
ER -